Lancet neurology
-
Review Meta Analysis
Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.
Reliable data on the prevalence and predictors of post-stroke dementia are needed to inform patients and carers, plan services and clinical trials, ascertain the overall burden of stroke, and understand its causes. However, published data on the prevalence and risk factors for pre-stroke and post-stroke dementia are conflicting. We undertook this systematic review to assess the heterogeneity in the reported rates and to identify risk factors for pre-stroke and post-stroke dementia. ⋯ None.
-
Randomized Controlled Trial
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome. The 5-year active treatment extension compares the effects of early and delayed treatment with interferon beta-1b on time to clinically definite multiple sclerosis (CDMS) and other disease outcomes, including disability progression. ⋯ Bayer Schering Pharma.
-
As the average human lifespan extends and medical care improves, there are more individuals above the age of 80 years who have a high quality of life. However, these very elderly individuals are particularly susceptible to stroke. ⋯ Although there has been an under-representation of the very elderly in studies of stroke therapy, these treatments might be of benefit to this group of patients. Indeed, emerging data indicate that the use of several of these therapies in routine clinical practice in the very elderly can be effective.